[1]
|
Roth, G.A., Mensah, G.A., Johnson, C.O., et al. (2020) Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 2019 Study. Journal of the American College of Cardiology, 76, 2982-3021.
https://doi.org/10.1016/j.jacc.2020.11.010
|
[2]
|
Mach, F., Baigent, C., Catapano, A.L., et al. (2020) 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. European Heart Journal, 41, 111-188.
https://doi.org/10.1093/eurheartj/ehz455
|
[3]
|
Esan, O. and Wierzbicki, A.S. (2021) Triglycerides and Cardiovascu-lar Disease. Current Opinion in Cardiology, 36, 469-477. https://doi.org/10.1097/HCO.0000000000000862
|
[4]
|
Nordestgaard, B.G., Benn, M., Schnohr, P. and Tybja-erg-Hansen, A. (2007) Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women. JAMA, 298, 299-308.
https://doi.org/10.1001/jama.298.3.299
|
[5]
|
Duran, E.K. and Pradhan, A.D. (2021) Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease. Clinical Chemistry, 67, 183-196. https://doi.org/10.1093/clinchem/hvaa296
|
[6]
|
Jepsen, A.M.K., Langsted, A., Varbo, A., Bang, L.E., Kamstrup, P.R. and Nordestgaard, B.G. (2016) Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortal-ity in 5414 Patients with Ischemic Heart Disease. Clinical Chemistry, 62, 593-604. https://doi.org/10.1373/clinchem.2015.253757
|
[7]
|
Cao, Y.X., Zhang, H.W., Jin, J.L., et al. (2020) The Longitu-dinal Association of Remnant Cholesterol with Cardiovascular Outcomes in Patients with Diabetes and Pre-Diabetes. Cardiovascular Diabetology, 19, Article No. 104.
https://doi.org/10.1186/s12933-020-01076-7
|
[8]
|
Ginsberg, H.N., Packard, C.J., Chapman, M.J., et al. (2021) Tri-glyceride-Rich Lipoproteins and Their Remnants: Metabolic Insights, Role in Atherosclerotic Cardiovascular Disease, and Emerging Therapeutic Strategies—A Consensus Statement from the European Atherosclerosis Society. European Heart Journal, 42, 4791-4806.
https://doi.org/10.1093/eurheartj/ehab551
|
[9]
|
Castañer, O., Pintó, X., Subirana, I., et al. (2020) Remnant Choles-terol, Not LDL Cholesterol, Is Associated with Incident Cardiovascular Disease. Journal of the American College of Cardiology, 76, 2712-2724.
https://doi.org/10.1016/j.jacc.2020.10.008
|
[10]
|
Wadström, B.N., Wulff, A.B., Pedersen, K.M., Jensen, G.B. and Nordestgaard, B.G. (2022) Elevated Remnant Cholesterol Increases the Risk of Peripheral Artery Disease, Myocardial Infarction, and Ischaemic Stroke: A Cohort-Based Study. European Heart Journal, 43, 3258-3269. https://doi.org/10.1093/eurheartj/ehab705
|
[11]
|
Xu, J., Qu, P., Du, X., et al. (2021) Change in Postprandial Level of Remnant Cholesterol after a Daily Breakfast in Chinese Patients with Hypertension. Frontiers in Cardiovascular Medi-cine, 8, Article 685385.
https://doi.org/10.3389/fcvm.2021.685385
|
[12]
|
Chen, M.M., Huang, X., Xu, C., et al. (2022) High Remnant Cho-lesterol Level Potentiates the Development of Hypertension. Frontiers in Endocrinology, 13, Article 830347. https://doi.org/10.3389/fendo.2022.830347
|
[13]
|
Doi, T., Langsted, A. and Nordestgaard, B.G. (2022) Elevated Remnant Cholesterol Reclassifies Risk of Ischemic Heart Disease and Myocardial Infarction. Journal of the American College of Cardiology, 79, 2383-2397.
https://doi.org/10.1016/j.jacc.2022.03.384
|
[14]
|
Wang, J., Jin, R., Jin, X., et al. (2023) Separate and Joint Associa-tions of Remnant Cholesterol Accumulation and Variability with Carotid Atherosclerosis: A Prospective Cohort Study. Journal of the American Heart Association, 12, e029352. https://doi.org/10.1161/JAHA.122.029352
|
[15]
|
Navarese, E.P., Vine, D., Proctor, S., et al. (2023) Independent Causal Effect of Remnant Cholesterol on Atherosclerotic Cardiovascular Outcomes: A Mendelian Randomization Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 43, e373-e380. https://doi.org/10.1161/ATVBAHA.123.319297
|
[16]
|
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A.B., Frikke-Schmidt, R. and Nordestgaard, B.G. (2013) Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease. Journal of the American College of Cardiology, 61, 427-436. https://doi.org/10.1016/j.jacc.2012.08.1026
|
[17]
|
Nordestgaard, B.G., Nicholls, S.J., Langsted, A., Ray, K.K. and Tybjærg-Hansen, A. (2018) Advances in Lipid-Lowering Therapy through Gene-Silencing Technologies. Nature Re-views Cardiology, 15, 261-272.
https://doi.org/10.1038/nrcardio.2018.3
|
[18]
|
Kaltoft, M., Langsted, A. and Nordestgaard, B.G. (2020) Triglycerides and Remnant Cholesterol Associated with Risk of Aortic Valve Stenosis: Mendelian Randomization in the Copenhagen General Population Study. European Heart Journal, 41, 2288-2299. https://doi.org/10.1093/eurheartj/ehaa172
|
[19]
|
Vallejo-Vaz, A.J., Fayyad, R., Boekholdt, S.M., et al. (2018) Tri-glyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events among Patients Receiving Statin Therapy in the TNT Trial. Circulation, 138, 770-781.
https://doi.org/10.1161/CIRCULATIONAHA.117.032318
|
[20]
|
Tsunoda, F., Asztalos, I.B., Horvath, K.V., Steiner, G., Schaefer, E.J. and Asztalos, B.F. (2016) Fenofibrate, HDL, and Cardiovascular Disease in Type-2 Diabetes: The DAIS Trial. Atherosclerosis, 247, 35-39.
https://doi.org/10.1016/j.atherosclerosis.2016.01.028
|
[21]
|
Toth, P.P., Hamon, S.C., Jones, S.R., et al. (2016) Effect of Alirocumab on Specific Lipoprotein Non-High-Density Lipoprotein Cholesterol and Subfractions as Measured by the Vertical Auto Profile Method: Analysis of 3 Randomized Trials versus Placebo. Lipids in Health and Disease, 15, Arti-cle No. 28. https://doi.org/10.1186/s12944-016-0197-4
|